Program Offering and Eligibility

Program offering

If you have been prescribed HEMLIBRA and you are eligible, you may be able to get help with your drug costs.

The program helps with $15,000 per year in drug co-pay costs. You pay as little as $5 per co-pay per treatment.

Patients may owe more than $5 depending on how the health insurance plan applies manufacturer co-pay assistance to out-of-pocket costs.

Eligibility

You are eligible if you:
  • Have been prescribed HEMLIBRA for an FDA-approved indication
  • Are 18 years of age or older, or have a legal guardian 18 years of age or older to manage the program
  • Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance marketplaces
  • Do not receive support from the Genentech Patient Foundation or any other independent co-pay assistance foundations for HEMLIBRA
  • Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (eg, Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD or TRICARE)
  • Do not reside in a state where the program is prohibited

 

If you are not eligible for the HEMLIBRA Co-pay Program, there may be other options for co-pay assistance. Call (866) HEMLIBRA (866-436-5427) or visit HEMLIBRA.com/access to learn more.

Indication and Important Safety Information

 

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include:

  • Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
  • Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head

Carefully follow your healthcare provider's instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.

The most common side effects of HEMLIBRA include: injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.

What else should I know about HEMLIBRA?

See the detailed "Instructions for Use" that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.

  • Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
  • You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care.

These are not all of the possible side effects of HEMLIBRA. Speak to your healthcare provider for medical advice about side effects.

Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.